CA2293664A1 - Fsh-releasing peptides - Google Patents
Fsh-releasing peptides Download PDFInfo
- Publication number
- CA2293664A1 CA2293664A1 CA002293664A CA2293664A CA2293664A1 CA 2293664 A1 CA2293664 A1 CA 2293664A1 CA 002293664 A CA002293664 A CA 002293664A CA 2293664 A CA2293664 A CA 2293664A CA 2293664 A1 CA2293664 A1 CA 2293664A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- seq
- recited
- xaa
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010059616 Activins Proteins 0.000 title abstract description 22
- 102000005606 Activins Human genes 0.000 title abstract description 21
- 239000005557 antagonist Substances 0.000 claims abstract description 12
- 230000035558 fertility Effects 0.000 claims abstract description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 154
- 238000000034 method Methods 0.000 claims description 46
- 241001465754 Metazoa Species 0.000 claims description 38
- 230000028327 secretion Effects 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 4
- -1 prolyl ethyl amide Chemical compound 0.000 claims description 4
- 230000002483 superagonistic effect Effects 0.000 claims description 4
- 239000002676 xenobiotic agent Substances 0.000 claims description 4
- 230000002034 xenobiotic effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 239000003488 releasing hormone Substances 0.000 abstract description 8
- 241000235789 Hyperoartia Species 0.000 abstract description 7
- 230000003389 potentiating effect Effects 0.000 abstract description 5
- 150000001413 amino acids Chemical class 0.000 description 83
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 58
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 58
- 229940028334 follicle stimulating hormone Drugs 0.000 description 58
- 102000009151 Luteinizing Hormone Human genes 0.000 description 43
- 108010073521 Luteinizing Hormone Proteins 0.000 description 43
- 229940040129 luteinizing hormone Drugs 0.000 description 43
- 108010048818 seryl-histidine Proteins 0.000 description 35
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 28
- 230000003578 releasing effect Effects 0.000 description 25
- YBDOQKVAGTWZMI-XIRDDKMYSA-N His-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N YBDOQKVAGTWZMI-XIRDDKMYSA-N 0.000 description 23
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 18
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 18
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 18
- VDUJEEQMRQCLHB-YTQUADARSA-N Trp-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O VDUJEEQMRQCLHB-YTQUADARSA-N 0.000 description 17
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 17
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 14
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 14
- YZMPDHTZJJCGEI-BQBZGAKWSA-N Ser-His Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 YZMPDHTZJJCGEI-BQBZGAKWSA-N 0.000 description 14
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 11
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108010065920 Insulin Lispro Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 description 7
- 102000006771 Gonadotropins Human genes 0.000 description 6
- 108010086677 Gonadotropins Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000002622 gonadotropin Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000972773 Aulopiformes Species 0.000 description 5
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000002267 hypothalamic effect Effects 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- HQMLIDZJXVVKCW-UWTATZPHSA-N (2r)-2-aminopropanamide Chemical compound C[C@@H](N)C(N)=O HQMLIDZJXVVKCW-UWTATZPHSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 3
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010081398 FSH-RF receptor Proteins 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 3
- 102000008238 LHRH Receptors Human genes 0.000 description 3
- 108010021290 LHRH Receptors Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical compound NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 210000003442 median eminence Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- JNVXACSECVMTSD-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1h-imidazol-5-yl)-1-oxopropa Chemical compound NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 JNVXACSECVMTSD-XJIZABAQSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- FAQYEASGXHQQAA-XIRDDKMYSA-N His-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CN=CN3)N FAQYEASGXHQQAA-XIRDDKMYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101500022509 Lithobates catesbeianus Gonadoliberin-2 Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- DFZVZEMNPGABKO-SSDOTTSWSA-N (2r)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-SSDOTTSWSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101800000478 Gonadoliberin-3 Proteins 0.000 description 1
- 108700015863 His(5)-Trp(7)-Tyr(8)- LHRH Proteins 0.000 description 1
- GMIWMPUGTFQFHK-KCTSRDHCSA-N His-Ala-Trp Chemical compound C[C@H](NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O GMIWMPUGTFQFHK-KCTSRDHCSA-N 0.000 description 1
- VGYOLSOFODKLSP-IHPCNDPISA-N His-Leu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 VGYOLSOFODKLSP-IHPCNDPISA-N 0.000 description 1
- BNBQSLZMHBFEIV-TUSQITKMSA-N His-Trp-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CN=CN1 BNBQSLZMHBFEIV-TUSQITKMSA-N 0.000 description 1
- JATYGDHMDRAISQ-KKUMJFAQSA-N His-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O JATYGDHMDRAISQ-KKUMJFAQSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 241000252498 Ictalurus punctatus Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000251745 Petromyzon marinus Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- CICQXRWZNVXFCU-SRVKXCTJSA-N Ser-His-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O CICQXRWZNVXFCU-SRVKXCTJSA-N 0.000 description 1
- NBUKGEFVZJMSIS-XIRDDKMYSA-N Ser-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CO)N NBUKGEFVZJMSIS-XIRDDKMYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- VDCGPCSLAJAKBB-XIRDDKMYSA-N Trp-Ser-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)N VDCGPCSLAJAKBB-XIRDDKMYSA-N 0.000 description 1
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 1
- ULHJJQYGMWONTD-HKUYNNGSSA-N Tyr-Gly-Trp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O ULHJJQYGMWONTD-HKUYNNGSSA-N 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 210000001971 anterior hypothalamus Anatomy 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000006408 female gonad development Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108010087791 pyroglutamylhistidine Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Lamprey LHRH-III is a potent FSH-releasing factor, and may be used to enhance fertility. Antagonists to lamprey LHRH-III may be used to inhibit fertility.
Description
FSH-RELEASING PEPT)(DES
This invention was made with support from the United States Government under Grants DK43900 and MH51853 awarded by the National Institutes of Health. The United States Government has certain rights in this invention.
The benefit of the 04 June 1997 filing date of provisional application serial number 60/nnn,nnn (which was a conversion of nonprovisional application serial number 08/869,153) is claimed under 35 U.S.C. ~ 119(e) in the United States. The benefit of the 04 June 1997 filing date of application serial number 08/869,153 is claimed under applicable treaties and conventions outside the United States.
TECHNICAL FIELD
This invention pertains to compositions and methods for selectively stimulating or inhibiting the release of follicle-stimulating hormone from the anterior lobe of the pituitary gland.
BACKGROUND ART
The brain controls the release of gonadotropin hormones from the anterior pituitary gland. Two important gonadotropins are follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH is critical for spermatogenesis and for ovarian follicle development, while LH is critical to androgen secretion in males, and estrogen secretion, ovulation, and formation of the corpus luteum in females. A hormone with specific activity for releasing FSH but not LH could be used to increase fertility in humans or other animals, or to correct fertility problems caused by defective hypothalamic control of FSH secretion.
Conversely, antisera or other antagonists to an FSH-specific releasing factor will inhibit FSH secretion, thereby inhibiting spermatogenesis in males, or inhibiting development of follicles and ovarian development in females, providing a new antifertility drug. It is also possible that very high doses of an FSH-specific releasing factor will inhibit FSH secretion, rather than stimulate it.
This invention was made with support from the United States Government under Grants DK43900 and MH51853 awarded by the National Institutes of Health. The United States Government has certain rights in this invention.
The benefit of the 04 June 1997 filing date of provisional application serial number 60/nnn,nnn (which was a conversion of nonprovisional application serial number 08/869,153) is claimed under 35 U.S.C. ~ 119(e) in the United States. The benefit of the 04 June 1997 filing date of application serial number 08/869,153 is claimed under applicable treaties and conventions outside the United States.
TECHNICAL FIELD
This invention pertains to compositions and methods for selectively stimulating or inhibiting the release of follicle-stimulating hormone from the anterior lobe of the pituitary gland.
BACKGROUND ART
The brain controls the release of gonadotropin hormones from the anterior pituitary gland. Two important gonadotropins are follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH is critical for spermatogenesis and for ovarian follicle development, while LH is critical to androgen secretion in males, and estrogen secretion, ovulation, and formation of the corpus luteum in females. A hormone with specific activity for releasing FSH but not LH could be used to increase fertility in humans or other animals, or to correct fertility problems caused by defective hypothalamic control of FSH secretion.
Conversely, antisera or other antagonists to an FSH-specific releasing factor will inhibit FSH secretion, thereby inhibiting spermatogenesis in males, or inhibiting development of follicles and ovarian development in females, providing a new antifertility drug. It is also possible that very high doses of an FSH-specific releasing factor will inhibit FSH secretion, rather than stimulate it.
Prior indirect evidence has suggested that separate factors could be responsible for triggering the release of FSH and for triggering the release of LH in mammals.
However, this hypothesis could not previously be confirmed, because no previous work successfully isolated a potent factor that selectively induces the release of FSH, but not LH. See McCann, S. et al., Control of follicle-stimulating hormone and luteinizing hormone release by hypothalamic peptides, Annals New York Academy of Sciences, 687:55-59, 1993;
Dees, W.
et al., Ethanol and the pulsatile release of luteinizing hormone, follicle stimulating hormone and prolactin in ovariectomized rats, Alcohol, 2:641-646, 1985; Dhariwal, A.
et al., Separation of follicle-stimulating hormone-releasing factor from luteinizing hormone-releasing factor, Endocrinology, 76:290-294, 1965; Dhariwal, A. et al., Chromatographic behavior of follicle stimulating hormone-releasing factor on Sephadex and carboxy methyl cellulose, Neuroendocrinology, 2:294-303, 1967; Igarashi, M. et al., A hypothalamic follicle stimulating hormone-releasing factor,. Endocrinology, 74:446-452, 1964; Lumpkin, M. et al., Effect of destruction of the dorsal anterior hypothalamus on follicle-stimulating hormone secretion in the rat, Endocrinology, 115:2473-2480, 1984; Samson, W. et al., Chromatographic and biologic analysis of ME and OVLT LHRH, Peptides, 1:97-102, 1980; Mizunuma, H., et al., Evidence for an FSH-releasing factor in the posterior portion of the rat median eminence, Life Sci., 33:2003-2009, 1983.
Luteinizing hormone releasing hormone (LHRH, also known as gonadotropin-releasing hormone, or GnRH) has both LH-releasing activity and FSH-releasing activity.
See Schally, A. et al., Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones, Science, 173:1036-1038, 1971; and D.
Lincoln, Gonadotropin-releasing hormone (GnRH): basic physiology, pp. 218-229 in L.
DeGroot et al., Endocrinology, 1995. The latter states at page 218: "There is no convincing evidence for the existence of a separate and specific FSH-releasing hormone, although some components of the GnRH precursor and some GnRH analogues appear to differ in the degree to which they stimulate the secretion of the two gonadotropins."
Sower, S. et al., Primary structure and biological activity of a third gonadotropin releasing hormone from lamprey brain, Endocrinology, 132:1125-1131, 1993 reported the structure of lamprey GnRH-III (referred to as 1-LHRH-III in this specification), and reported that it stimulated estradiol and progesterone release from Petromyzon marinus (lamprey) ovaries. (Lampreys, jawless fish, are representatives of what is generally considered to be the most primitive of the extant classes of vertebrates.) Lamprey I-LHRH-I has been reported to have relatively low activity in releasing either FSH or LH in rats. Yu, W. et al., Selective FSH-releasing activity of [D-Trp~]GAP,_13:
However, this hypothesis could not previously be confirmed, because no previous work successfully isolated a potent factor that selectively induces the release of FSH, but not LH. See McCann, S. et al., Control of follicle-stimulating hormone and luteinizing hormone release by hypothalamic peptides, Annals New York Academy of Sciences, 687:55-59, 1993;
Dees, W.
et al., Ethanol and the pulsatile release of luteinizing hormone, follicle stimulating hormone and prolactin in ovariectomized rats, Alcohol, 2:641-646, 1985; Dhariwal, A.
et al., Separation of follicle-stimulating hormone-releasing factor from luteinizing hormone-releasing factor, Endocrinology, 76:290-294, 1965; Dhariwal, A. et al., Chromatographic behavior of follicle stimulating hormone-releasing factor on Sephadex and carboxy methyl cellulose, Neuroendocrinology, 2:294-303, 1967; Igarashi, M. et al., A hypothalamic follicle stimulating hormone-releasing factor,. Endocrinology, 74:446-452, 1964; Lumpkin, M. et al., Effect of destruction of the dorsal anterior hypothalamus on follicle-stimulating hormone secretion in the rat, Endocrinology, 115:2473-2480, 1984; Samson, W. et al., Chromatographic and biologic analysis of ME and OVLT LHRH, Peptides, 1:97-102, 1980; Mizunuma, H., et al., Evidence for an FSH-releasing factor in the posterior portion of the rat median eminence, Life Sci., 33:2003-2009, 1983.
Luteinizing hormone releasing hormone (LHRH, also known as gonadotropin-releasing hormone, or GnRH) has both LH-releasing activity and FSH-releasing activity.
See Schally, A. et al., Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones, Science, 173:1036-1038, 1971; and D.
Lincoln, Gonadotropin-releasing hormone (GnRH): basic physiology, pp. 218-229 in L.
DeGroot et al., Endocrinology, 1995. The latter states at page 218: "There is no convincing evidence for the existence of a separate and specific FSH-releasing hormone, although some components of the GnRH precursor and some GnRH analogues appear to differ in the degree to which they stimulate the secretion of the two gonadotropins."
Sower, S. et al., Primary structure and biological activity of a third gonadotropin releasing hormone from lamprey brain, Endocrinology, 132:1125-1131, 1993 reported the structure of lamprey GnRH-III (referred to as 1-LHRH-III in this specification), and reported that it stimulated estradiol and progesterone release from Petromyzon marinus (lamprey) ovaries. (Lampreys, jawless fish, are representatives of what is generally considered to be the most primitive of the extant classes of vertebrates.) Lamprey I-LHRH-I has been reported to have relatively low activity in releasing either FSH or LH in rats. Yu, W. et al., Selective FSH-releasing activity of [D-Trp~]GAP,_13:
comparison with gonadotropin-releasing abilities of analogs of GAP and natural LHRHs, Brain Res. Bull., 25:867-873, 1990.
Schally, A. et al., Re-examination of porcine and bovine hypothalamic fractions for additional luteinizing hormone and follicle stimulating hormone-releasing activities, Endocrinology, 98:380-391, 1976 reported that in vivo FSH-releasing activity could not be separated from LH-releasing activity from porcine hypothalami by fractionation on Sephadex, and concluded that there was only one gonadotropin-releasing hormone (GnRH).
By contrast, Lumpkin, M. et al., Purification of FSH-releasing factor: Its dissimilarity from LHRH of mammalian, avian, and piscian origin, Brain Res. Bull., 18:175-178, 1987 reported that FSH-releasing activity was separated from the LH-releasing activity in ovine hypothalami on Sephadex G-25, but did not isolate the factor causing FSH
release.
Neurons that are immunopositive for 1-LHRH-I have been identified in human hypothalami, projecting from the arcuate region to the median eminence. Stops, E. et al, Polygenic expression of gonadotropin-releasing hormone (GnRH) in human?, Peptides, 9:419-423, 1988.
Lincoln, D., Luteinizing Hormone-Releasing Hormone, pp. 142-151 in DeGroot et al.
(ed), Endocrinology, 1989, discloses various agonists and antagonists for mammalian LHRH.
W. Yu et al., "A hypothalamic follicle-stimulating hormone-releasing decapeptide in the rat," Proc. Natl. Acad. Sci. USA, 94:9499-9503, 1997 discloses some of the work reported in the present specification, but is not believed to constitute prior art.
United States patent 4,973,577 discloses a 28,000 dalton protein isolated from porcine follicular fluid that stimulates the release of FSH, but not of LH. This protein has a relatively slow onset of action, and is relatively difficult to synthesize. The protein was said to be a homodimer of two chains of 116 amino acid residues each, or 232 residues total.
United States patent 3,888,836 discloses a method for synthesizing mammalian LHRH. Mammalian LHRH causes increased serum levels of both LH and FSH.
United States patent 4,721,775 discloses certain peptides that non-selectively induce the secretion of both LH and FSH.
.30 Attempts in our laboratory to purify FSH-releasing factor (FSH-RF} by fractionation of lamb hypothalami (discussed in some of the papers cited above) were successful only at certain seasons of the year, and even then we found that activity was lost after samples were stored at -20°C (unpublished data). Thus our prior work did not successfully isolate or identify the putative FSH-releasing factor.
Schally, A. et al., Re-examination of porcine and bovine hypothalamic fractions for additional luteinizing hormone and follicle stimulating hormone-releasing activities, Endocrinology, 98:380-391, 1976 reported that in vivo FSH-releasing activity could not be separated from LH-releasing activity from porcine hypothalami by fractionation on Sephadex, and concluded that there was only one gonadotropin-releasing hormone (GnRH).
By contrast, Lumpkin, M. et al., Purification of FSH-releasing factor: Its dissimilarity from LHRH of mammalian, avian, and piscian origin, Brain Res. Bull., 18:175-178, 1987 reported that FSH-releasing activity was separated from the LH-releasing activity in ovine hypothalami on Sephadex G-25, but did not isolate the factor causing FSH
release.
Neurons that are immunopositive for 1-LHRH-I have been identified in human hypothalami, projecting from the arcuate region to the median eminence. Stops, E. et al, Polygenic expression of gonadotropin-releasing hormone (GnRH) in human?, Peptides, 9:419-423, 1988.
Lincoln, D., Luteinizing Hormone-Releasing Hormone, pp. 142-151 in DeGroot et al.
(ed), Endocrinology, 1989, discloses various agonists and antagonists for mammalian LHRH.
W. Yu et al., "A hypothalamic follicle-stimulating hormone-releasing decapeptide in the rat," Proc. Natl. Acad. Sci. USA, 94:9499-9503, 1997 discloses some of the work reported in the present specification, but is not believed to constitute prior art.
United States patent 4,973,577 discloses a 28,000 dalton protein isolated from porcine follicular fluid that stimulates the release of FSH, but not of LH. This protein has a relatively slow onset of action, and is relatively difficult to synthesize. The protein was said to be a homodimer of two chains of 116 amino acid residues each, or 232 residues total.
United States patent 3,888,836 discloses a method for synthesizing mammalian LHRH. Mammalian LHRH causes increased serum levels of both LH and FSH.
United States patent 4,721,775 discloses certain peptides that non-selectively induce the secretion of both LH and FSH.
.30 Attempts in our laboratory to purify FSH-releasing factor (FSH-RF} by fractionation of lamb hypothalami (discussed in some of the papers cited above) were successful only at certain seasons of the year, and even then we found that activity was lost after samples were stored at -20°C (unpublished data). Thus our prior work did not successfully isolate or identify the putative FSH-releasing factor.
Other studies in our laboratory confirmed FSH-releasing activity by incubating stalk median eminence (SME)-extracts in vitro with hemipituitaries from male rats.
VJe confirmed the FSH-releasing activity of sheep and rat SME extracts in this assay, and found that the FSH-releasing activity emerged from columns of Sephadex G-25 just prior to emergence of LHRH, similar to results we had seen in an in vivo assay in ovariectomized, estrogen- and progesterone-blocked female rats. Even where we were able to extract crude or partially purified fractions showing selective FSH-releasing activity, that activity was relatively low compared to the activity of fractions with LH-releasing activity (unpublished data).
Our laboratory also screened known LHRH's from various species for selective FSH-releasing activity; and we also evaluated the activity of 25 analogs of LHRH
in in vivo assays.
(LHRH's from various species are disclosed in Lumpkin et al., 1987.) One analog was found to have only FSH-releasing activity, but its potency was very low, and the slope of its dose-response curve was flat. Of the known forms of LHRH from other species, we found that only chicken (c) LHRH-II had slightly preferential FSH-releasing activity in vivo (unpublished data).
DISCLOSURE OF INVENTION
We have unexpectedly discovered that 1-LHRH-III is the long-sought FSH-releasing factor. This activity has been confirmed in vitro by incubation with hemi-anterior pituitaries of adult male rats. Following intravenous injection at the lowest dose tested to date (10 picomoles), this peptide produced an increase in FSH in vivo (P < 0.01) within ten minutes, but no significant increase in LH. Such a selective effect has not previously been reported for any analog of mammalian LHRH.
MODES FOR CARRYING OUT THE INVENTION _ Structure of Vertebrate LIiRII's Tested 5 Mammal pGlu-His-Trp-Ser-Tyr-Gly-Leu-ArQ-(SEQ. ID
Pro-Gly-NHZ NO. 2) (m-LHRH) Lamprey III pGiu-His-Trp-Ser-His-Asp-Trp-Lys-(SEQ. ID
Pro-Gly-NHz NO. 1) (1-LHRH-III) Lamprey I pGlu-His-Tyr-Ser-Leu-Glu-Trp-Lys-(SEQ. ID
Pro-Gly-NHZ NO. 3) (1-LHRH-I) Salmon pGlu-His-Trp-Ser-Tyr-Gly-Trp-Leu-(SEQ. ID
Pro-Gly-NHz NO. 4) (s-LHRH) Chicken II pGlu-His=frp-Ser-His-Gly-Trp-Tyr-(SEQ. ID
Pro-Gly-NHS NO. 5) (c-LHRH-II) General Adult male and female Sprague-Dawley rats (Holtzmann, Madison, WI; 200-250 g) were housed two per cage under controlled conditions of temperature (23-25°C) and lighting (on from 0500 to 1700 hr). The animals had free access to a pellet diet and to tap water.
The 1-LHRH-III used in the experiments reported here was synthesized by standard solid-state peptide synthesis methods, and was purified to greater than 97%
purity by preparative reverse-phase high performance liquid chromatography. All other peptides used were purchased from Peninsula Laboratories (Belmont, CA), except as otherwise noted.
The significance of differences among muitiple groups was determined by analysis of variance, with subsequent Newman-Keuls multiple comparisons at each point.
Student's t-test was used to determine the significance of differences between two groups.
In vitro studies . 30 . After acclimatization for 5 or more days in the vivarium, male rats were killed by decapitation. Following removal of the posterior lobe, the anterior pituitary (AP) was bisected longitudinally, and each AP was incubated in a tube containing 0.5 ml Krebs-Ringer bicarbonate (5 mM ascorbic acid; pH 7.4) buffer (KRB) in an atmosphere of 95 %
OZ/5 % COZ
in a Dubnoff shaker (50 cycles per min) for a period of b0 min. Following this pre-incubation period, the APs were incubated for 3 hr in fresh KRB buffer alone (control), or in KRB containing one of various concentrations of synthetic mammalian (m}-LHRH, 1-LHRH-__ III, 1-LHRH-I, chicken (c)-LHRH-II, or salmon (s}-LHRH. The medium was then aspirated, and was stored frozen at -20°C until radio-immunoassays (RIA) for FSH
and LH were conducted. FSH and LH were measured using kits supplied by the National Institute of Arthritis Digestive Diabetes and Kidney Disease; hormone values were expressed in terms of NIH-rFSH-RP-2 and NIH-rLH-RP-3 standards. The experiments were repeated twice.
The inter- and infra-assay coefficients of variation for FSH assays were 7.5 % and 5.2 % , respectively; and were 6.5 % and 4.8 % for LH assays.
In vivo studies Female rats were ovariectomized under anesthesia with isoflurane 4 weeks prior to the in vivo experiments. Three days before blood sampling, each ovariectomized rat was injected subcutaneously with SO icg estradiol benzoate (Sigma Chemical Co., St. Louis, MO) dissolved in 0.1 ml sesame oil, and 25 mg progesterone (Eli Lilly, Indianapolis, IN) dissolved in 0.5 ml sesame oil. One day prior to testing, each animal was implanted with a jugular-atrial catheter.
On the morning of testing, polyethylene tubing (PE-50) was connected to the distal end of the jugular-atrial catheter on the rat's dorsum to facilitate blood sampling and intravenous injection. Animals were acclimatized one hour before initial blood samples were taken.
Heparinized blood samples (5 ml) were collected just before, and at 10, 30, and 60 minutes after injection of 0.5 ml isotonic saline or 1-LHRH-III (10 or 100 pmole) in 0.5 ml isotonic saline. After removal of each blood sample, an equal volume of isotonic saline was administered to maintain blood volume.
Effects of 1-LHRH 1, 1 LHRH 111, and Mammalian (m)-LIIRH on FSH Release In Vitro Lamprey 1-LHRH-III caused FSH release in a dose-related fashion, with a minimal effective concentration (MEC) of 10-9 M (the lowest concentration tested) or lower, and a maximal effect at about 10'6 M. Thereafter, release of FSH levelled off through the highest concentration tested (10'° M).
Lamprey 1-LHRH-I caused a small but statistically significant release of FSH
at a concentration of 10-s M; the amount of FSH released was significantly less than that caused by 1-LHRH-III at the two concentrations tested (10~ and 10-5 M). By contrast, m-LHRH
produced equivalent levels of FSH release at the two concentrations tested {4 x 10-9 and 2 x 10 -g M) as compared to the levels induced by I-LHRH-III. See Table 2.
VJe confirmed the FSH-releasing activity of sheep and rat SME extracts in this assay, and found that the FSH-releasing activity emerged from columns of Sephadex G-25 just prior to emergence of LHRH, similar to results we had seen in an in vivo assay in ovariectomized, estrogen- and progesterone-blocked female rats. Even where we were able to extract crude or partially purified fractions showing selective FSH-releasing activity, that activity was relatively low compared to the activity of fractions with LH-releasing activity (unpublished data).
Our laboratory also screened known LHRH's from various species for selective FSH-releasing activity; and we also evaluated the activity of 25 analogs of LHRH
in in vivo assays.
(LHRH's from various species are disclosed in Lumpkin et al., 1987.) One analog was found to have only FSH-releasing activity, but its potency was very low, and the slope of its dose-response curve was flat. Of the known forms of LHRH from other species, we found that only chicken (c) LHRH-II had slightly preferential FSH-releasing activity in vivo (unpublished data).
DISCLOSURE OF INVENTION
We have unexpectedly discovered that 1-LHRH-III is the long-sought FSH-releasing factor. This activity has been confirmed in vitro by incubation with hemi-anterior pituitaries of adult male rats. Following intravenous injection at the lowest dose tested to date (10 picomoles), this peptide produced an increase in FSH in vivo (P < 0.01) within ten minutes, but no significant increase in LH. Such a selective effect has not previously been reported for any analog of mammalian LHRH.
MODES FOR CARRYING OUT THE INVENTION _ Structure of Vertebrate LIiRII's Tested 5 Mammal pGlu-His-Trp-Ser-Tyr-Gly-Leu-ArQ-(SEQ. ID
Pro-Gly-NHZ NO. 2) (m-LHRH) Lamprey III pGiu-His-Trp-Ser-His-Asp-Trp-Lys-(SEQ. ID
Pro-Gly-NHz NO. 1) (1-LHRH-III) Lamprey I pGlu-His-Tyr-Ser-Leu-Glu-Trp-Lys-(SEQ. ID
Pro-Gly-NHZ NO. 3) (1-LHRH-I) Salmon pGlu-His-Trp-Ser-Tyr-Gly-Trp-Leu-(SEQ. ID
Pro-Gly-NHz NO. 4) (s-LHRH) Chicken II pGlu-His=frp-Ser-His-Gly-Trp-Tyr-(SEQ. ID
Pro-Gly-NHS NO. 5) (c-LHRH-II) General Adult male and female Sprague-Dawley rats (Holtzmann, Madison, WI; 200-250 g) were housed two per cage under controlled conditions of temperature (23-25°C) and lighting (on from 0500 to 1700 hr). The animals had free access to a pellet diet and to tap water.
The 1-LHRH-III used in the experiments reported here was synthesized by standard solid-state peptide synthesis methods, and was purified to greater than 97%
purity by preparative reverse-phase high performance liquid chromatography. All other peptides used were purchased from Peninsula Laboratories (Belmont, CA), except as otherwise noted.
The significance of differences among muitiple groups was determined by analysis of variance, with subsequent Newman-Keuls multiple comparisons at each point.
Student's t-test was used to determine the significance of differences between two groups.
In vitro studies . 30 . After acclimatization for 5 or more days in the vivarium, male rats were killed by decapitation. Following removal of the posterior lobe, the anterior pituitary (AP) was bisected longitudinally, and each AP was incubated in a tube containing 0.5 ml Krebs-Ringer bicarbonate (5 mM ascorbic acid; pH 7.4) buffer (KRB) in an atmosphere of 95 %
OZ/5 % COZ
in a Dubnoff shaker (50 cycles per min) for a period of b0 min. Following this pre-incubation period, the APs were incubated for 3 hr in fresh KRB buffer alone (control), or in KRB containing one of various concentrations of synthetic mammalian (m}-LHRH, 1-LHRH-__ III, 1-LHRH-I, chicken (c)-LHRH-II, or salmon (s}-LHRH. The medium was then aspirated, and was stored frozen at -20°C until radio-immunoassays (RIA) for FSH
and LH were conducted. FSH and LH were measured using kits supplied by the National Institute of Arthritis Digestive Diabetes and Kidney Disease; hormone values were expressed in terms of NIH-rFSH-RP-2 and NIH-rLH-RP-3 standards. The experiments were repeated twice.
The inter- and infra-assay coefficients of variation for FSH assays were 7.5 % and 5.2 % , respectively; and were 6.5 % and 4.8 % for LH assays.
In vivo studies Female rats were ovariectomized under anesthesia with isoflurane 4 weeks prior to the in vivo experiments. Three days before blood sampling, each ovariectomized rat was injected subcutaneously with SO icg estradiol benzoate (Sigma Chemical Co., St. Louis, MO) dissolved in 0.1 ml sesame oil, and 25 mg progesterone (Eli Lilly, Indianapolis, IN) dissolved in 0.5 ml sesame oil. One day prior to testing, each animal was implanted with a jugular-atrial catheter.
On the morning of testing, polyethylene tubing (PE-50) was connected to the distal end of the jugular-atrial catheter on the rat's dorsum to facilitate blood sampling and intravenous injection. Animals were acclimatized one hour before initial blood samples were taken.
Heparinized blood samples (5 ml) were collected just before, and at 10, 30, and 60 minutes after injection of 0.5 ml isotonic saline or 1-LHRH-III (10 or 100 pmole) in 0.5 ml isotonic saline. After removal of each blood sample, an equal volume of isotonic saline was administered to maintain blood volume.
Effects of 1-LHRH 1, 1 LHRH 111, and Mammalian (m)-LIIRH on FSH Release In Vitro Lamprey 1-LHRH-III caused FSH release in a dose-related fashion, with a minimal effective concentration (MEC) of 10-9 M (the lowest concentration tested) or lower, and a maximal effect at about 10'6 M. Thereafter, release of FSH levelled off through the highest concentration tested (10'° M).
Lamprey 1-LHRH-I caused a small but statistically significant release of FSH
at a concentration of 10-s M; the amount of FSH released was significantly less than that caused by 1-LHRH-III at the two concentrations tested (10~ and 10-5 M). By contrast, m-LHRH
produced equivalent levels of FSH release at the two concentrations tested {4 x 10-9 and 2 x 10 -g M) as compared to the levels induced by I-LHRH-III. See Table 2.
Table 2 Group FSH (ng/ml) KRB (control) 97.7 20.4 ~5 m-LHRH, 4 x 109 M ** 218.5 35.7 m-LHRH, 2 x 10-8 M ** 257.5 42.4 - 1-LHRH-III, 10-9 M * 228.3 52.5 1-LHRH-III, 10-$ M ** 255.7 42.4 I-LHRH-III, 10'' M *** 213.0 17.9 1-LHRH-III, 10-6 M ** 278.2 40.9 1-LHRH-III, 10'5 M ** 283.0 60.8 I-LHRH-III, 10~ M **** 368.6 40.9 I-LHRH-I, 10~ M * 164.0 29.3 1-LHRH-I, 10-5 M ** 178.2 17.0 n = 6 in each case; * signifies p < 0.05; ** signifies p < 0.01; *** signifies p < 0.001; and **** signifies p < 0.0001 versus KRB control Effect of 1-LFIRH 1, 1-LHRH Ill, and m-LIIRH on LH Release In Vitro In contrast to its effects on FSH release, I-LHRH-III had a much weaker effect on LH
release. In fact, I-LHRH-III only caused the release of significant and comparable concentrations of LH at the three highest concentrations tested (10'6 -10'° M). We found that I-LHRH-I was inactive at the two concentrations tested (10-6 and 10'5 M).
Mammalian LHRH
gave a dose-related stimulatory effect on LH release, and was active at the lowest concentration tested (4 x 10-9 M). See Table 3.
release. In fact, I-LHRH-III only caused the release of significant and comparable concentrations of LH at the three highest concentrations tested (10'6 -10'° M). We found that I-LHRH-I was inactive at the two concentrations tested (10-6 and 10'5 M).
Mammalian LHRH
gave a dose-related stimulatory effect on LH release, and was active at the lowest concentration tested (4 x 10-9 M). See Table 3.
Table 3 Group ~ (~~~) KRB (control) 139.3 t 16.9 S m-LHRH, 4 x 10'9 M 183.1 t 27.0 m-LHRH, 2 x 10'e M ** 262.0 t 36.1 1-LHRH-III, 10'9 M 171.8 27.3 1-LHRH-III, 10'e M 165.7 t 26.6 I-LHRH-III, 10'' M 179.9 28.4 1-LHRH-III, 10'6 M * 233.6 33.8 1-LHRH-III, 10-5 M * 202.9 31.2 1-LHRH-III, 10~ M ** 236.6 19.3 1-LHRH-I, 10-6 M 134.1 23.2 1-LHRH-I, 10'5 M 120.4 8.1 n = 6 in each case; * signifies p < 0.05; ** signifies p < 0.01; versus KRB
control ?0 Effects of Salmon and Chicken LFIRH II on Gonadotropin Release In Vitro Salmon (s)-LHRH stimulated the release of both FSH and LH at the two concentrations tested (10 ~' and 106 M). See Tables 4 and S. Chicken (c) LHRH-II stimulated LH release at doses from 10-8 to 10-° M, but the dose effect was not statistically significant.
The c-LHRH-II had equivalent LH-releasing activity to that of m-LHRH, but 1-LHRH-III
showed no LH-releasing activity in this experiment. The c-LHRH-II only significantly increased FSH release at the highest concentration tested (10 ~ M). In this experiment, the MEC for 1-LHRH-III for a statistically significant release of FSH was two orders of magnitude lower than that for c-LHRH-II.
control ?0 Effects of Salmon and Chicken LFIRH II on Gonadotropin Release In Vitro Salmon (s)-LHRH stimulated the release of both FSH and LH at the two concentrations tested (10 ~' and 106 M). See Tables 4 and S. Chicken (c) LHRH-II stimulated LH release at doses from 10-8 to 10-° M, but the dose effect was not statistically significant.
The c-LHRH-II had equivalent LH-releasing activity to that of m-LHRH, but 1-LHRH-III
showed no LH-releasing activity in this experiment. The c-LHRH-II only significantly increased FSH release at the highest concentration tested (10 ~ M). In this experiment, the MEC for 1-LHRH-III for a statistically significant release of FSH was two orders of magnitude lower than that for c-LHRH-II.
Table 4 Group ~ FSH (ng/ml) KRB (control) 157.5 t 13.2 ~5 m-LHRH, 2 x 10'8 M ** 320.5 t 42.6 1-LHRH-III, 10'~ M 196.3 t 21.2 1-LHRH-III, 10'8 M * 249.3 31.3 1-LHRH-III, 10~' M * 203.2 16.4 1-LHRH-III, 10-6 M 215.0 38.0 c-LHRH-II, 10-8 M 123.7 18.0 c-LHRH-II, 10'' M 209.3 44.0 c-LHRH-II, 10'6 M *** 263.7 17.8 s-LHRH, 10 M * 233.0 37.4 s-LHRH, 10'6 M 203.2 t 39.2 n = 6 in each case; * signifies p < 0.05; ** signifies p < 0.01; and ***
signifies p < 0.001 versus KRB control Table 5 Group LH (ng/ml) KRB (control) 149.3 17.0 5 m-LHRH, 2 x 10-8 M * 214.7 30.3 1-LHRH-III, 10-9 M 158.7 10.2 - 1-LHRH-III, 10-8 M 163.2 6.5 1-LHRH-III, 10-' M 182.7 t 13.7 1-LHRH-III, 10-6 M 176.0 t 9.3 10 c-LHRH-II, 10'8 M * 199.3 13.6 c-LHRH-II, 10-' M * 216.3 17.7 c-LHRH-II, 10-6 M * 239.0 31.7 s-LHRH, 10-' M * 230.8 38.8 s-LHRH, 10~ M 186.2 13.6 n = 6 in each case; * signifies p < 0.05 versus KRB control Effects of 1-LFIRH 111 on FSII and LH Release In Vivo Saline-injected control animals experienced a significant decline in plasma FSH levels 10 minutes after injection, followed by a return to levels that did not differ significantly from pre-injection FSH levels by 30- and 60-minutes post-injection (data not shown).
Compared to the control animals, animals injected with the lowest dose of 1-LHRH-III
(10 pmole) showed a highly significant increase in plasma FSH 10 minutes after injection, an effect that vanished by 30 minutes post-injection. See Table 6. Increasing the dose of 1-LHRH-III to 100 pmole produced a slightly greater effect at 10 minutes that was maintained minutes after injection. Thus the 100 pmole dose caused a more prolonged effect than the 10 pmole dose.
signifies p < 0.001 versus KRB control Table 5 Group LH (ng/ml) KRB (control) 149.3 17.0 5 m-LHRH, 2 x 10-8 M * 214.7 30.3 1-LHRH-III, 10-9 M 158.7 10.2 - 1-LHRH-III, 10-8 M 163.2 6.5 1-LHRH-III, 10-' M 182.7 t 13.7 1-LHRH-III, 10-6 M 176.0 t 9.3 10 c-LHRH-II, 10'8 M * 199.3 13.6 c-LHRH-II, 10-' M * 216.3 17.7 c-LHRH-II, 10-6 M * 239.0 31.7 s-LHRH, 10-' M * 230.8 38.8 s-LHRH, 10~ M 186.2 13.6 n = 6 in each case; * signifies p < 0.05 versus KRB control Effects of 1-LFIRH 111 on FSII and LH Release In Vivo Saline-injected control animals experienced a significant decline in plasma FSH levels 10 minutes after injection, followed by a return to levels that did not differ significantly from pre-injection FSH levels by 30- and 60-minutes post-injection (data not shown).
Compared to the control animals, animals injected with the lowest dose of 1-LHRH-III
(10 pmole) showed a highly significant increase in plasma FSH 10 minutes after injection, an effect that vanished by 30 minutes post-injection. See Table 6. Increasing the dose of 1-LHRH-III to 100 pmole produced a slightly greater effect at 10 minutes that was maintained minutes after injection. Thus the 100 pmole dose caused a more prolonged effect than the 10 pmole dose.
Table 6 Group Change in FSH from baseline, 10 minutes post-injection (ng/ml) saline -3.85 0.82 1-LHItH-III, 10 pmole ** -0.75 t 0.37 1-LHItH-III, 100 pmole ** -0.43 0.61 n = 6 in each case, except n = 7 for 1-LHRH-III, 100 pmole; ** signifies p <
0.01 versus saline control Injection of saline diluent produced a slight decrease in LH plasma concentration i0 minutes post-injection, an effect that continued for the duration of the experiment, but that was not statistically significant. Neither the 10 pmole nor the 100 pmole dose of 1-LHItH-III
produced a statistically significant difference in LH levels versus saline control at any of the times measured. See Table 7.
Table 7 Group Change in LH from baseline, 10 minutes post-injection (ng/tnl) saline -0.070 0.122 1-LHItH-III, 10 pmole -0.022 0.078 1-LHItH-III, 100 pmole 0.097 t 0.077 n = 6 in each case, except n = 7 for 1-LHRH-III, 100 pmole; the measured values were not significantly different from one another.
Thus I-LHItH-III caused the release of FSH in_ vivo, but not LH, at each of the two doses tested, 10 pmole and 100 pmole.
As these results have demonstrated, I-LHItH-III is the first highly specific and potent FSH-releasing peptide discovered. The 1-LHRH-III behaves completely differently from the other polypeptides tested. We found that 1-LHRH-I had minimal potency to release either FSH or LH. Salmon LHRH and chicken LHRH-II had low potency, and lacked specificity for FSH release. The in vivo assays using the other known vertebrate LHRH's showed that only one of them, c-LHRH-II, possessed even slight selectivity for FSH
release.
We conclude that 1-LHRH-III is a highly conserved peptide in vertebrates, and in particular that it or a closely related peptide is the mammalian peptide hormone responsible for the potent and specific release of FSH. If I-LHRH-III is not identical to the mammalian FSH-RF, the degree of homology between the two is quite high.
Mammalian m-LHRH and 1-LHRH-III were approximately equipotent toward releasing FSH. The decreased potency of I-LHRH-III toward releasing LH is probably accounted for by the fact that 1-LHRH-II1 only has 60% homology with m-LHRH (see Table 1).
The differences in sequences are accounted for by the differing amino acids in positions 5-8, which presumably cause a drastic decrease in LH-releasing activity and an increase in FSH-releasing capabilities. It is probable that the tetrapeptide 1-LHRH-III 5-8 binds to the active site of a putative specific FSH-RF receptor. Presumably, the FSH-RF receptor confers this specificity for FSH release, whereas the LHRH receptors stimulate the release of both hormones, albeit with a greater sensitivity for LH than FSH release. FSH-RF receptors may reside on gonadotropes that contain only FSH. LHRH receptors may cause release of both hormones from gonadotropes that contain both FSH and LH. LHRH receptors may also be located on gonadotropes that only contain LH.
Pulsatile gonadotropin release in the rat is characterized by simultaneous pulses of FSH and LH, by pulses of LH alone, and by pulses of FSH alone. We hypothesize that the first two types of pulses may be accounted for by LHRH, and the third by FSH-RF.
The discovery of FSH-RF has important implications for veterinary and human medicine. For example, treatment of farm animals with FSH-RF should lead to maturation of increased . numbers of ovarian follicles and subsequent ovulations, leading to increased litter sizes. FSH-RF may be used as a drug to increase fertility in humans.
Related peptides are expected to be agonists or "superagonists" of 1-LHRH-III.
These agonists will be prepared and tested in similar assays. Particular examples include peptides in which (a) the Aspb amino acid residue has been replaced with another amino acid residue (naturally occurring or xenobiotic); or (b) in which the Pro9 residue has been replaced with ProNHEt (prolyl ethyl amide) and the Gly'°-NHZ has been deleted; or (c) both. Examples of such agonists include the following:
0.01 versus saline control Injection of saline diluent produced a slight decrease in LH plasma concentration i0 minutes post-injection, an effect that continued for the duration of the experiment, but that was not statistically significant. Neither the 10 pmole nor the 100 pmole dose of 1-LHItH-III
produced a statistically significant difference in LH levels versus saline control at any of the times measured. See Table 7.
Table 7 Group Change in LH from baseline, 10 minutes post-injection (ng/tnl) saline -0.070 0.122 1-LHItH-III, 10 pmole -0.022 0.078 1-LHItH-III, 100 pmole 0.097 t 0.077 n = 6 in each case, except n = 7 for 1-LHRH-III, 100 pmole; the measured values were not significantly different from one another.
Thus I-LHItH-III caused the release of FSH in_ vivo, but not LH, at each of the two doses tested, 10 pmole and 100 pmole.
As these results have demonstrated, I-LHItH-III is the first highly specific and potent FSH-releasing peptide discovered. The 1-LHRH-III behaves completely differently from the other polypeptides tested. We found that 1-LHRH-I had minimal potency to release either FSH or LH. Salmon LHRH and chicken LHRH-II had low potency, and lacked specificity for FSH release. The in vivo assays using the other known vertebrate LHRH's showed that only one of them, c-LHRH-II, possessed even slight selectivity for FSH
release.
We conclude that 1-LHRH-III is a highly conserved peptide in vertebrates, and in particular that it or a closely related peptide is the mammalian peptide hormone responsible for the potent and specific release of FSH. If I-LHRH-III is not identical to the mammalian FSH-RF, the degree of homology between the two is quite high.
Mammalian m-LHRH and 1-LHRH-III were approximately equipotent toward releasing FSH. The decreased potency of I-LHRH-III toward releasing LH is probably accounted for by the fact that 1-LHRH-II1 only has 60% homology with m-LHRH (see Table 1).
The differences in sequences are accounted for by the differing amino acids in positions 5-8, which presumably cause a drastic decrease in LH-releasing activity and an increase in FSH-releasing capabilities. It is probable that the tetrapeptide 1-LHRH-III 5-8 binds to the active site of a putative specific FSH-RF receptor. Presumably, the FSH-RF receptor confers this specificity for FSH release, whereas the LHRH receptors stimulate the release of both hormones, albeit with a greater sensitivity for LH than FSH release. FSH-RF receptors may reside on gonadotropes that contain only FSH. LHRH receptors may cause release of both hormones from gonadotropes that contain both FSH and LH. LHRH receptors may also be located on gonadotropes that only contain LH.
Pulsatile gonadotropin release in the rat is characterized by simultaneous pulses of FSH and LH, by pulses of LH alone, and by pulses of FSH alone. We hypothesize that the first two types of pulses may be accounted for by LHRH, and the third by FSH-RF.
The discovery of FSH-RF has important implications for veterinary and human medicine. For example, treatment of farm animals with FSH-RF should lead to maturation of increased . numbers of ovarian follicles and subsequent ovulations, leading to increased litter sizes. FSH-RF may be used as a drug to increase fertility in humans.
Related peptides are expected to be agonists or "superagonists" of 1-LHRH-III.
These agonists will be prepared and tested in similar assays. Particular examples include peptides in which (a) the Aspb amino acid residue has been replaced with another amino acid residue (naturally occurring or xenobiotic); or (b) in which the Pro9 residue has been replaced with ProNHEt (prolyl ethyl amide) and the Gly'°-NHZ has been deleted; or (c) both. Examples of such agonists include the following:
pGlu-His-Trp-Ser-His-Asp-Trp-Lys-(ProNHEt) (SEQ. ID NO. 6) pGlu-His-Trp-Ser-His-Ala-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 7) pGlu-His-Trp-Ser-His-Ala-Trp-Lys-(ProNHEt) (SEQ. ID NO. 8) pGlu-His-Trp-Ser-His-(D-Ala)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 9) pGlu-His-Trp-Ser-His-(D-Ala)-Trp-Lys-(ProNHEt) (SEQ. ID NO. 10) pGlu-His-Trp-Ser-His-Leu-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 11) pGlu-His-Trp-Ser-His-Leu-Trp-Lys-(ProNHEt) (SEQ. ID NO. 12) pGlu-His-Trp-Ser-His-(D-Leu)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 13) pGlu-His-Trp-Ser-His-(D-Leu)-Trp-Lys-(ProNHEt) (SEQ. ID NO. 14) pGlu-His-Trp-Ser-His-(SerBu~-Trp-Lys-Pro-Gly-NHz (SEQ. ID NO. 15) pGlu-His-Trp-Ser-His-(SerBu')-Trp-Lys-(ProNHEt) {SEQ. ID NO. 16) pGlu-His-Trp-Ser-His-(D-SerBu')-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 17) pGlu-His-Trp-Ser-His-(D-SerBu')-Trp-Lys-(ProNHEt) (SEQ. ID NO. 18) pGlu-His-Trp-Ser-His-Trp-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 19) pGlu-His-Trp-Ser-His-Trp-Trp-Lys-(ProNHEt) (SEQ. ID NO. 20) pGlu-His-Trp-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 21) pGlu-His-Trp-Ser-His-(D-Trp)-Trp-Lys-(ProNHEt) (SEQ. ID NO. 22) pGlu-His-Trp-Ser-His-(His-Bzl)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 23) pGlu-His-Trp-Ser-His-(His-Bzl)-Trp-Lys-(ProNHEt) (SEQ. ID NO. 24) -pGlu-His-Trp-Ser-His-(D-His-Bzl)-Trp-Lys-Pro-Gly-NHZ {SEQ. ID NO. 25) pGlu-His-Trp-Ser-His-(D-His-Bzl)-Trp-Lys-(ProNHEt) (SEQ. ID NO. 26) pGlu-His-Trp-Ser-His-Nal(2)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 27) pGlu-His-Trp-Ser-His-Nal(2)-Trp-Lys-(ProNHEt) (SEQ. ID NO. 28) pGlu-His-Trp-Ser-His-(D-Nal(2)}-Trp-Lys-Pro-Gly-NHz (SEQ. ID NO. 29) pGlu-His-Trp-Ser-His-(D-Nal(2))-Trp-Lys-(ProNHEt) (SEQ. ID NO. 30) pGlu-His-Trp-Ser-His-Nal(2)-Trp-Lys-Pro-(aza-Gly)-NHZ (SEQ. ID NO. 31) pGlu-His-Trp-Ser-His-(D-Nal(2))-Trp-Lys-Pro-(aza-Gly)-NHZ (SEQ. ID NO. 32) Note: "(aza-Gly)-NHZ" in SEQ. ID NOs. 31 and 32 denotes -NH-NH-CONHZ.
Converseiy, inhibitory analogs of the peptide, or antibodies against the peptide, may be used as potent antifertility drugs. Monoclonal or polyclonal antibodies against the peptide may be raised using standard techniques, initially conjugating the peptide to a carrier such as bovine serum albumin or keyhole limpet hemocyanin. Particular examples of antagonists include peptides in which one or more of residues 1, 2, 3, 6, and 10 have been replaced with another amino acid residue (naturally occurring or xenobiotic). Examples of such antagonists include the following:
pGlu-(D-Phe)-Trp-Ser-His-(D-Ala)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 33) pGlu-(D-Phe)-(D-Trp)-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NH2 (SEQ. ID NO. 34) (D-pyro-Glu)-(D-Phe)-(D-Trp)-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO.
35) WO 98!55136 PCT/US98l11512 (N-Ac-D-Phe)-(D-p-Cl-Phe)-{D-Trp)-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NHZ (SEQ.
ID NO. 3b) (N-Ac-D-p-CI-Phe)-(Ac-D-p-Cl-Phe)-(D-Trp)-Ser-His-(D-Phe)-Trp-Lys-Pro-(D-Ala)-5 NHZ (SEQ. ID NO. 37) (N-Ac-D-p-CI-Phe)-(Ac-D-p-CI-Phe)-(D-Trp)-Ser-His-(D-Arg)-Trp-Lys-Pro-(D-Ala)-NHZ (SEQ. ID NO. 38) 10 (N-Ac-D-Nal(2))-(p-F-D-Phe)-(D-Trp)-Ser-His-(D-Arg)-Trp-Lys-Pro-Gly-NHz (SEQ.
ID NO. 39) (N-Ac-D-Nal(2))-(D-p-CI-Phe)-(D-Trp)-Ser-His-(D-L-Arg-Et2)-Trp-Lys-Pro-(D-Ala}-NHZ (SEQ. ID NO. 40) (N-Ac-D-Nal(2))-(D-p-Cl-Phe)-(D-3-Pal)-Ser-His-{D-Arg)-(D-Trp)-Lys-Pro-(D-Ala)-NHz (SEQ. ID NO. 41) The effect of the peptide, its agonists, and its antagonists will be characterized in rats, and then in large mammals, such as sheep and pigs. After successful testing in large mammals, in vivo tests in primates will be conducted, in monkeys and in humans, in accordance with applicable laws and regulations.
The peptide, an agonist, or an antagonist, combined with a pharmaceutically acceptable carrier, may be administered to mammals, including humans, intravenously, subcutaneously, percutaneously, intramuscularly, or intranasally to increase fertility. It may also be administered to other vertebrates to increase fertility, for example sheep, cattle, pigs, chickens, turkeys, channel catfish, tilapia, and koi.
The active compound may be administered as a pharmaceutically acceptable salt, such . 30 as an acid addition salt; metal complex, e.g. with zinc, iron; or the like (which are considered salts for purposes herein). Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulfate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate, and the like. Intravenous or other injections may be administered in isotonic saline, phosphate buffers, and the like.
The dosage will vary depending on the specific purpose for which the peptide is administered; appropriate dosages may readily be determined by those of skill in the art, an "effective amount" being that which elevates or depresses serum FSH levels by a statistically significant amount, or that which enhances or inhibits fertility to a statistically significant degree.
For example, a patient experiencing infertility of unknown cause may be tested for 1-LHRH-III or FSH deficit through means otherwise known in the art, such as radioimmunoassay. Abnormally low FSH levels may indicate a deficiency in 1-LHRIi-III.
Such patients may be tested for a positive response to exogenous 1-LHRH-III.
If administration of exogenous 1-LHRH-III produces an increase in FSH, that Ending indicates that administration of exogenous 1-LHRH-III is a potential treatment for infertility.
As may prove most economical, the l-LHRH-III may be synthesized through any of various means known in the art, for example, synthesis on a solid-state peptide synthesizer, or expression of a cloned gene in E. coli.
The complete disclosures of all references cited in this specification are hereby incorporated by reference. In the event of an otherwise irreconcilable conflict, however, the present specification shall control.
SEQUENCE FISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: McCann, Samuel M.
Yu, Wen H.
(ii) TITLE OF INVENTION: FSH-Releasing Peptides IO
(iii) NUMBER OF SEQUENCES: 41 {iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: John H. Runnels 15 (B) STREET: P. 0. Box 2471 (C) CITY: Baton Rouge (D) STATE: LA
(E) COUNTRY: USA
(F) ZIP: 70821-2471 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25;
WordPerfect 5.1 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
3O {B) FILING DATE:
{C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Runnels, John H.
35 (B) REGISTRATION NUMBER: 33451 (C) REFERENCE/DOCKET NUMBER: 9703P.1 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (504) 387-3221 40 (B) TELEFAX: (504) 346-8049 (2) INFORMATION
FOR SEQ
ID NO:
l:
45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 50 (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu;
Xaa at is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Xaa His Trp Ser His Asp Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:2: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is gyro-Glu; Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa (2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Xaa His Tyr Ser Leu Glu Trp Lys Pro Xaa 1 5 to (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is gyro-Glu; Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Xaa His Trp Ser Tyr Gly Trp Leu Pro Xaa (2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids S (B) TYPE: amino acid ' (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= ~~Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
Xaa His Trp Ser His Gly Txp Tyr Pro Xaa {2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= ~~Xaa at 1 is pyro-Glu; Xaa at 9 i6 (PrONHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Xaa His Trp Ser His Asp Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
Xaa His Trp Ser His Ala Txp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:8: -(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids 5 (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
Xaa His Trp Ser His Ala Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 6 is (D-Ala); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Ala); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:10:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
(xi) .SEQUENCE DESCRIPTION: SEQ ID N0:11:
IS
Xaa His Txp Ser His Leu Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
Xaa His Trp Ser His Leu Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) .FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Leu);
Xaa at is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Xaa His Txp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:14: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Leu) ; Xaa at 9 is (ProNHEt) "
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (SerBut); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
Xaa His Txp Ser His Xaa Tzp Lys Pro Xaa 1 s to (2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (SerBut); Xaa at 9 is (ProNHEt)"
SO (xi) SEQBENCE DESCRIPTION: SEQ ID N0:16:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide i0 (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 6 is (D-SerBut); Xaa at 10 is Gly-NH2"
IS (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
Xaa His Tzp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
6 is (D-SerBut) ; X~ at 9FORMATP O~~E ; ate= "Xaa at 1 is pyro-Glu; Xaa at (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Xaa His Tzp Ser His Xaa Txp Lys Xaa 3S 1 s (2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
Xaa His Trp Ser His Trp Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:20: -(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide lO (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at is pyro-Glu;
1 Xaa at 9 is (ProNHEt) "
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
Xaa His Tzp Ser His Trp Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at is pyro-Glu;
1 Xaa at 30 6 is (D-Trp); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
Xaa His Tzp Ser His Xaa Trp Lys Pro Xaa 3S 1 s to (2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at is pyro-Glu;
1 Xaa at 6 is (D-Trp); Xaa at 9 is (ProNHEt)"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
Xaa His Tzp Ser His Xaa Tzp Lys Xaa 1. 5 (2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (His-Bzl); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
Xaa His Trp Ser His Xaa Tzp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid 2S (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (His-Bzl); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:24:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-His-Bzl); Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:25:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:26: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULfi TYPE: peptide IO (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 6 is (His-Bzl); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:
IS
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is Nal(2); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:27:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa 3S 1 5 i o (2) INFORMATION FOR SEQ ID N0:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is Nal(2); Xaa at 9 is (ProNHEt)"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:28:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Nal(2)); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:29:
IS
Xaa His Trp Ser His Xaa Tzp Lys Pro Xaa (2} INFORMATION FOR SEQ ID N0:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Nal(2)); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:30:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is Nal(2); Xaa at 10 is (aza-Gly)"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:31:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:32: -(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids $ (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide lO (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu;
Xaa at 6 is (D-Nal(2)); Xaa at 10 is (aza-Gly)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:32:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:33:
..0 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu;
Xaa at 30 2 is (D-Phe); Xaa at 6 is (D-Ala); Xaa at Gly-NH2"
is (xi) SEQUENCE DESCRIPTION: SEQ ID N0:33:
Xaa Xaa Trp Ser His Xaa Trp Lys Pro Xaa 35 1 s to (2) INFORMATION FOR SEQ ID N0:34:
(i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu;
Xaa at 2 is (D-Phe) : Xaa at 3 is (D-Trp) ; Xaa is (D-Trp) ; Xaa at at 6 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:34:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa SS
(2) INFORMATION FOR SEQ ID N0:35: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 0 (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (D-pyro-Glu); Xaa at 2 is (D-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Trp); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:35:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-Phe); Xaa at 2 is (D-p-C1-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Trp); Xaa at 10 is Gly-NH2"
3S (xi) SEQUENCE DESCRIPTION: SEQ ID N0:36:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-p-C1-Phe); Xaa at 2 is (Ac-D-p-C1-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Phe); Xaa at 10 is (D-Ala-NH2)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:37:
SS Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:38: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids $ (B} TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 10 ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-p-C1-Phe); Xaa at 2 is (Ac-D-p-C1-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Arg); Xaa at 10 is (D-Ala-NH2)"
IS
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:38:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids 25 (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 30 (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-Nal(2)); Xaa at 2 is (p-F-D-Phe); Xaa at 3 is (D-Txp);
Xaa at 6 is (D-Arg); Xaa at 10 is Gly-NH2"
3S (xi) SEQUENCE DESCRIPTION: SEQ ID N0:39:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-Nal(2)); Xaa at 2 is (D-p-C1-Phe); Xaa at 3 is (D-Trp);
Xaa at 6 is (D-L-Arg-Et2); Xaa at 10 is (D-Ala-NH2)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:40:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is (N-Ac-D-Nal(2)); Xaa at 2 is (D-p-C1-Pize); Xaa at 3 is (D-3-Pal); Xaa at 6 is (D-Arg); Xaa at 7 is (D-Trp); Xaa at 10 is (D-Ala-NH2)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:41:
Xaa Xaa Xaa Ser His Xaa Xaa Lys Pro Xaa
Converseiy, inhibitory analogs of the peptide, or antibodies against the peptide, may be used as potent antifertility drugs. Monoclonal or polyclonal antibodies against the peptide may be raised using standard techniques, initially conjugating the peptide to a carrier such as bovine serum albumin or keyhole limpet hemocyanin. Particular examples of antagonists include peptides in which one or more of residues 1, 2, 3, 6, and 10 have been replaced with another amino acid residue (naturally occurring or xenobiotic). Examples of such antagonists include the following:
pGlu-(D-Phe)-Trp-Ser-His-(D-Ala)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO. 33) pGlu-(D-Phe)-(D-Trp)-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NH2 (SEQ. ID NO. 34) (D-pyro-Glu)-(D-Phe)-(D-Trp)-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NHZ (SEQ. ID NO.
35) WO 98!55136 PCT/US98l11512 (N-Ac-D-Phe)-(D-p-Cl-Phe)-{D-Trp)-Ser-His-(D-Trp)-Trp-Lys-Pro-Gly-NHZ (SEQ.
ID NO. 3b) (N-Ac-D-p-CI-Phe)-(Ac-D-p-Cl-Phe)-(D-Trp)-Ser-His-(D-Phe)-Trp-Lys-Pro-(D-Ala)-5 NHZ (SEQ. ID NO. 37) (N-Ac-D-p-CI-Phe)-(Ac-D-p-CI-Phe)-(D-Trp)-Ser-His-(D-Arg)-Trp-Lys-Pro-(D-Ala)-NHZ (SEQ. ID NO. 38) 10 (N-Ac-D-Nal(2))-(p-F-D-Phe)-(D-Trp)-Ser-His-(D-Arg)-Trp-Lys-Pro-Gly-NHz (SEQ.
ID NO. 39) (N-Ac-D-Nal(2))-(D-p-CI-Phe)-(D-Trp)-Ser-His-(D-L-Arg-Et2)-Trp-Lys-Pro-(D-Ala}-NHZ (SEQ. ID NO. 40) (N-Ac-D-Nal(2))-(D-p-Cl-Phe)-(D-3-Pal)-Ser-His-{D-Arg)-(D-Trp)-Lys-Pro-(D-Ala)-NHz (SEQ. ID NO. 41) The effect of the peptide, its agonists, and its antagonists will be characterized in rats, and then in large mammals, such as sheep and pigs. After successful testing in large mammals, in vivo tests in primates will be conducted, in monkeys and in humans, in accordance with applicable laws and regulations.
The peptide, an agonist, or an antagonist, combined with a pharmaceutically acceptable carrier, may be administered to mammals, including humans, intravenously, subcutaneously, percutaneously, intramuscularly, or intranasally to increase fertility. It may also be administered to other vertebrates to increase fertility, for example sheep, cattle, pigs, chickens, turkeys, channel catfish, tilapia, and koi.
The active compound may be administered as a pharmaceutically acceptable salt, such . 30 as an acid addition salt; metal complex, e.g. with zinc, iron; or the like (which are considered salts for purposes herein). Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulfate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate, and the like. Intravenous or other injections may be administered in isotonic saline, phosphate buffers, and the like.
The dosage will vary depending on the specific purpose for which the peptide is administered; appropriate dosages may readily be determined by those of skill in the art, an "effective amount" being that which elevates or depresses serum FSH levels by a statistically significant amount, or that which enhances or inhibits fertility to a statistically significant degree.
For example, a patient experiencing infertility of unknown cause may be tested for 1-LHRH-III or FSH deficit through means otherwise known in the art, such as radioimmunoassay. Abnormally low FSH levels may indicate a deficiency in 1-LHRIi-III.
Such patients may be tested for a positive response to exogenous 1-LHRH-III.
If administration of exogenous 1-LHRH-III produces an increase in FSH, that Ending indicates that administration of exogenous 1-LHRH-III is a potential treatment for infertility.
As may prove most economical, the l-LHRH-III may be synthesized through any of various means known in the art, for example, synthesis on a solid-state peptide synthesizer, or expression of a cloned gene in E. coli.
The complete disclosures of all references cited in this specification are hereby incorporated by reference. In the event of an otherwise irreconcilable conflict, however, the present specification shall control.
SEQUENCE FISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: McCann, Samuel M.
Yu, Wen H.
(ii) TITLE OF INVENTION: FSH-Releasing Peptides IO
(iii) NUMBER OF SEQUENCES: 41 {iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: John H. Runnels 15 (B) STREET: P. 0. Box 2471 (C) CITY: Baton Rouge (D) STATE: LA
(E) COUNTRY: USA
(F) ZIP: 70821-2471 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
25 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25;
WordPerfect 5.1 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
3O {B) FILING DATE:
{C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Runnels, John H.
35 (B) REGISTRATION NUMBER: 33451 (C) REFERENCE/DOCKET NUMBER: 9703P.1 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (504) 387-3221 40 (B) TELEFAX: (504) 346-8049 (2) INFORMATION
FOR SEQ
ID NO:
l:
45 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear 50 (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu;
Xaa at is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Xaa His Trp Ser His Asp Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:2: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is gyro-Glu; Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:
Xaa His Trp Ser Tyr Gly Leu Arg Pro Xaa (2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:
Xaa His Tyr Ser Leu Glu Trp Lys Pro Xaa 1 5 to (2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is gyro-Glu; Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
Xaa His Trp Ser Tyr Gly Trp Leu Pro Xaa (2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids S (B) TYPE: amino acid ' (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= ~~Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:
Xaa His Trp Ser His Gly Txp Tyr Pro Xaa {2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid {D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= ~~Xaa at 1 is pyro-Glu; Xaa at 9 i6 (PrONHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:
Xaa His Trp Ser His Asp Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
{A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:
Xaa His Trp Ser His Ala Txp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:8: -(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids 5 (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:
Xaa His Trp Ser His Ala Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 6 is (D-Ala); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Ala); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:10:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is pyro-Glu; Xaa at 10 is Gly-NH2"
(xi) .SEQUENCE DESCRIPTION: SEQ ID N0:11:
IS
Xaa His Txp Ser His Leu Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:
Xaa His Trp Ser His Leu Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) .FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Leu);
Xaa at is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:
Xaa His Txp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:14: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Leu) ; Xaa at 9 is (ProNHEt) "
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (SerBut); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:
Xaa His Txp Ser His Xaa Tzp Lys Pro Xaa 1 s to (2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (SerBut); Xaa at 9 is (ProNHEt)"
SO (xi) SEQBENCE DESCRIPTION: SEQ ID N0:16:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide i0 (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 6 is (D-SerBut); Xaa at 10 is Gly-NH2"
IS (xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:
Xaa His Tzp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
6 is (D-SerBut) ; X~ at 9FORMATP O~~E ; ate= "Xaa at 1 is pyro-Glu; Xaa at (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
Xaa His Tzp Ser His Xaa Txp Lys Xaa 3S 1 s (2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:
Xaa His Trp Ser His Trp Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:20: -(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide lO (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at is pyro-Glu;
1 Xaa at 9 is (ProNHEt) "
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:
Xaa His Tzp Ser His Trp Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at is pyro-Glu;
1 Xaa at 30 6 is (D-Trp); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:
Xaa His Tzp Ser His Xaa Trp Lys Pro Xaa 3S 1 s to (2) INFORMATION FOR SEQ ID N0:22:
(i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at is pyro-Glu;
1 Xaa at 6 is (D-Trp); Xaa at 9 is (ProNHEt)"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:
Xaa His Tzp Ser His Xaa Tzp Lys Xaa 1. 5 (2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (His-Bzl); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:
Xaa His Trp Ser His Xaa Tzp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid 2S (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (His-Bzl); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:24:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-His-Bzl); Xaa at 10 is Gly-NH2"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:25:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:26: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids S (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULfi TYPE: peptide IO (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is gyro-Glu; Xaa at 6 is (His-Bzl); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:
IS
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is Nal(2); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:27:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa 3S 1 5 i o (2) INFORMATION FOR SEQ ID N0:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is Nal(2); Xaa at 9 is (ProNHEt)"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:28:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Nal(2)); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:29:
IS
Xaa His Trp Ser His Xaa Tzp Lys Pro Xaa (2} INFORMATION FOR SEQ ID N0:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is (D-Nal(2)); Xaa at 9 is (ProNHEt)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:30:
Xaa His Trp Ser His Xaa Trp Lys Xaa (2) INFORMATION FOR SEQ ID N0:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu; Xaa at 6 is Nal(2); Xaa at 10 is (aza-Gly)"
SO (xi) SEQUENCE DESCRIPTION: SEQ ID N0:31:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:32: -(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids $ (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide lO (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu;
Xaa at 6 is (D-Nal(2)); Xaa at 10 is (aza-Gly)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:32:
Xaa His Trp Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:33:
..0 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu;
Xaa at 30 2 is (D-Phe); Xaa at 6 is (D-Ala); Xaa at Gly-NH2"
is (xi) SEQUENCE DESCRIPTION: SEQ ID N0:33:
Xaa Xaa Trp Ser His Xaa Trp Lys Pro Xaa 35 1 s to (2) INFORMATION FOR SEQ ID N0:34:
(i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is pyro-Glu;
Xaa at 2 is (D-Phe) : Xaa at 3 is (D-Trp) ; Xaa is (D-Trp) ; Xaa at at 6 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:34:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa SS
(2) INFORMATION FOR SEQ ID N0:35: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 0 (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (D-pyro-Glu); Xaa at 2 is (D-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Trp); Xaa at 10 is Gly-NH2"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:35:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:36:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-Phe); Xaa at 2 is (D-p-C1-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Trp); Xaa at 10 is Gly-NH2"
3S (xi) SEQUENCE DESCRIPTION: SEQ ID N0:36:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID NO:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-p-C1-Phe); Xaa at 2 is (Ac-D-p-C1-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Phe); Xaa at 10 is (D-Ala-NH2)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:37:
SS Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:38: _ (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids $ (B} TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 10 ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-p-C1-Phe); Xaa at 2 is (Ac-D-p-C1-Phe); Xaa at 3 is (D-Trp); Xaa at 6 is (D-Arg); Xaa at 10 is (D-Ala-NH2)"
IS
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:38:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids 25 (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 30 (ix) FEATURE:
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-Nal(2)); Xaa at 2 is (p-F-D-Phe); Xaa at 3 is (D-Txp);
Xaa at 6 is (D-Arg); Xaa at 10 is Gly-NH2"
3S (xi) SEQUENCE DESCRIPTION: SEQ ID N0:39:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE
(D) OTHER INFORMATION: /note= "Xaa at 1 is (N-Ac-D-Nal(2)); Xaa at 2 is (D-p-C1-Phe); Xaa at 3 is (D-Trp);
Xaa at 6 is (D-L-Arg-Et2); Xaa at 10 is (D-Ala-NH2)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:40:
Xaa Xaa Xaa Ser His Xaa Trp Lys Pro Xaa (2) INFORMATION FOR SEQ ID N0:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE:
(D) OTHER INFORMATION:/note= "Xaa at 1 is (N-Ac-D-Nal(2)); Xaa at 2 is (D-p-C1-Pize); Xaa at 3 is (D-3-Pal); Xaa at 6 is (D-Arg); Xaa at 7 is (D-Trp); Xaa at 10 is (D-Ala-NH2)"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:41:
Xaa Xaa Xaa Ser His Xaa Xaa Lys Pro Xaa
Claims (77)
1. A method of altering the level of secretion of FSH in a vertebrate animal, comprising administering to the animal an effective amount of a peptide selected from the group consisting of an 1-LHRH-III agonist peptide; an 1-LHRH-III superagonist peptide; an 1-LHRH-III antagonist peptide; a peptide selected from the group consisting of SEQ. ID NO.
6 through SEQ. ID NO. 41; and 1-LHRH-III (SEQ. ID NO. 1); wherein the amount of the peptide administered causes a selective change in the serum FSH level of the animal, but does not cause a proportional change in the serum LH level of the animal.
6 through SEQ. ID NO. 41; and 1-LHRH-III (SEQ. ID NO. 1); wherein the amount of the peptide administered causes a selective change in the serum FSH level of the animal, but does not cause a proportional change in the serum LH level of the animal.
2. A method as recited in Claim 1, wherein the level of secretion of FSH in the animal is increased; said method comprising administering to the animal an effective amount of I-LHRH-III (SEQ. ID NO. 1).
3. A method as recited in Claim 2, wherein the animal is a mammal.
4. A method as recited in Claim 3, wherein the animal is a human.
5. A method as recited in Claim 4, wherein the human is male.
6. A method as recited in Claim 4, wherein the human is female.
7. A method of increasing the fertility of a vertebrate animal, comprising increasing the level of FSH secretion in the animal by the method of Claim 2.
8. A method as recited in Claim 7, wherein the animal is a mammal.
9. A method as recited in Claim 8, wherein the animal is a human.
10. A method as recited in Claim 9, wherein the human is male.
11. A method as recited in Claim 9, wherein the human is female.
12. A method as recited in Claim 1, wherein the level of secretion of FSH in the animal is increased; said method comprising administering to the animal an effective amount of an 1-LHRH-III agonist peptide or 1-LHRH-III superagonist peptide; wherein the amount of the peptide administered causes a selective increase in the serum FSH level of the animal, but does not cause a proportional increase in the serum LH level of the animal.
13. A method as recited in Claim 12, wherein the peptide is selected from the group consisting of decapeptides whose sequences are identical to the sequence of 1-LHRH-III
(SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or (b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of 1-LHRH-III is deleted.
(SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or (b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of 1-LHRH-III is deleted.
14. A method as recited in Claim 13, wherein the peptide is selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.
15. A method as recited in Claim 12, wherein the animal is a mammal.
16. A method as recited in Claim 15, wherein the animal is a human.
17. A method as recited in Claim 16, wherein the human is male.
18. A method as recited in Claim 16, wherein the human is female.
19. A method of increasing the fertility of a vertebrate animal, comprising increasing the level of FSH secretion in the animal by the method of Claim 12.
20. A method as recited in Claim 19, wherein the peptide is selected from the group consisting of decapeptides whose sequences are identical to the sequence of 1-LHRH-III
(SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or (b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of I-LHRH-III is deleted.
(SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or (b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of I-LHRH-III is deleted.
21. A method as recited in Claim 20, wherein the peptide is selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.
22. A method as recited in Claim 19, wherein the animal is a mammal.
23. A method as recited in Claim 19, wherein the animal is a human.
24. A method as recited in Claim 23, wherein the human is male.
25. A method as recited in Claim 23, wherein the human is female.
26. A method as recited in Claim 1, wherein the level of secretion of FSH in the animal is decreased; said method comprising administering to the animal an effective amount of an 1-LHRH-III antagonist peptide; wherein the amount of the peptide administered causes a selective decrease in the serum FSH level of the animal, but does not cause a proportional decrease in the serum LH level of the animal.
27. A method as recited in Claim 26, wherein the antagonist is selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.
28. A method as recited in Claim 26, wherein the animal is a mammal.
29. A method as recited in Claim 28, wherein the animal is a human.
30. A method as recited in Claim 29, wherein the human is male.
31. A method as recited in Claim 29, wherein the human is female.
32. A method of decreasing the fertility of a vertebrate animal, comprising decreasing the level of FSH secretion in the animal by the method of Claim 26.
33. A method as recited in Claim 32, wherein the antagonist is selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.
34. A method as recited in Claim 32, wherein the animal is a mammal.
35. A method as recited in Claim 34, wherein the animal is a human.
36. A method as recited in Claim 35, wherein the human is male.
37. A method as recited in Claim 35, wherein the human is female.
38. A composition selected from the group consisting of an I-LHRH-III agonist peptide; an 1-LHRH-III superagonist peptide; an 1-LHRH-III antagonist peptide;
a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 41;
and an effective amount of substantially pure 1-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier; wherein said composition has the property that said composition will, when administered in an effective amount to a vertebrate animal, cause a selective change in the serum FSH level of the animal, but will not cause a proportional change in the serum LH level of the animal.
a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 41;
and an effective amount of substantially pure 1-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier; wherein said composition has the property that said composition will, when administered in an effective amount to a vertebrate animal, cause a selective change in the serum FSH level of the animal, but will not cause a proportional change in the serum LH level of the animal.
39. A composition as recited in Claim 38, wherein said composition comprises an effective amount of substantially pure 1-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier.
40. A composition as recited in Claim 38, wherein said composition comprises a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID
NO. 32.
NO. 32.
41. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 6.
42. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 7.
43. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 8.
44. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 9.
45. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 10.
46. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 11.
47. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 12.
48. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 13.
49. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 14.
50. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 15.
51. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 16.
52. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 17.
53. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 18.
54. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 19.
55. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 20.
56. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 21.
57. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 22.
58. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 23.
59. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 24.
60. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 25.
61. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 26.
62. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 27.
63. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 28.
64. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 29.
65. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 30.
66. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 31.
67. A peptide as recited in Claim 40, wherein said peptide is SEQ. ID NO. 32.
68. A composition as recited in Claim 38, wherein said composition comprises a peptide selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID
NO. 41.
NO. 41.
69. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 33.
70. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 34.
71. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 35.
72. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 36.
73. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 37.
74. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 38.
75. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 39.
76. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 40.
77. A peptide as recited in Claim 68, wherein said peptide is SEQ. ID NO. 41.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86915397A | 1997-06-04 | 1997-06-04 | |
| US08/869,153 | 1997-06-04 | ||
| PCT/US1998/011512 WO1998055136A1 (en) | 1997-06-04 | 1998-06-03 | Fsh-releasing peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2293664A1 true CA2293664A1 (en) | 1998-12-10 |
Family
ID=25353027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002293664A Abandoned CA2293664A1 (en) | 1997-06-04 | 1998-06-03 | Fsh-releasing peptides |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0996457A4 (en) |
| JP (1) | JP2000513749A (en) |
| CA (1) | CA2293664A1 (en) |
| WO (1) | WO1998055136A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635740B1 (en) | 1997-03-27 | 2003-10-21 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Ligand/lytic peptide compositions and methods of use |
| HU221407B1 (en) | 1997-03-28 | 2002-09-28 | Gyula Magvasi | Active substance and composition inhibiting tumorous proliferation in ectoderm derived tissues and process for production thereof |
| DE10050831A1 (en) * | 2000-10-05 | 2002-05-02 | Veyx Pharma Gmbh | Procedure for starting the cycle in female breeding animals |
| CN101264096B (en) * | 2007-03-12 | 2011-11-09 | 中国医学科学院药物研究所 | Use of ginsenoside Rg1 in preparing spermatogenic product |
| JP5764854B2 (en) * | 2009-11-05 | 2015-08-19 | 株式会社サウスプロダクト | Polyclonal antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4721775A (en) * | 1985-08-26 | 1988-01-26 | Board Of Regents, The University Of Texas System | Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids |
| US4973577A (en) * | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
| CA2173727A1 (en) * | 1994-08-10 | 1996-02-22 | Sandor Lovas | Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof |
-
1998
- 1998-06-03 JP JP11502855A patent/JP2000513749A/en not_active Ceased
- 1998-06-03 CA CA002293664A patent/CA2293664A1/en not_active Abandoned
- 1998-06-03 WO PCT/US1998/011512 patent/WO1998055136A1/en not_active Application Discontinuation
- 1998-06-03 EP EP98926280A patent/EP0996457A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000513749A (en) | 2000-10-17 |
| EP0996457A1 (en) | 2000-05-03 |
| WO1998055136A1 (en) | 1998-12-10 |
| EP0996457A4 (en) | 2001-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5084555A (en) | An octapeptide bombesin analog | |
| EP1272206B1 (en) | A chicken II GnRH analog for use in reducing tumor cell growth | |
| JP4346115B2 (en) | LH-RH peptide analogues, their use and medicinal compositions containing them | |
| US8258100B2 (en) | Ligand/lytic peptide methods of use | |
| US6307017B1 (en) | Octapeptide bombesin analogs | |
| Kerdelhue et al. | Binding studies of substance P anterior pituitary binding sites: changes in substance P binding sites during the rat estrous cycle | |
| EP0559756B1 (en) | Nonapeptide bombesin antagonists | |
| EP0592512A1 (en) | NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS | |
| Haviv et al. | Active reduced-size hexapeptide analogs of luteinizing hormone-releasing hormone | |
| CA2293664A1 (en) | Fsh-releasing peptides | |
| CZ84893A3 (en) | Method of projecting and synthesizing lhrh antagonists | |
| Labrie et al. | Inhibition of luteinizing hormone release by analogs of luteinizing hormone-releasing hormone (LHRH) in vitro | |
| US6300471B1 (en) | FSH-releasing peptides | |
| EP0988048A1 (en) | Ligand/lytic peptide compositions and methods of use | |
| US6407205B1 (en) | FSH-releasing peptides | |
| Nekola et al. | LHRH antagonists in females | |
| US5382568A (en) | Decapeptide having dopamine stimulating activity | |
| US5593965A (en) | Anti-tumor effects of GnRH-III | |
| Coy et al. | Suppression of gonadotropin release and ovulation in animals by inhibitory analogs of luteinizing hormone-releasing hormone | |
| Schally et al. | Hypothalamic hormones regulating pituitary (and other) functions: their physiology and biochemistry as well as recent studies with their synthetic analogues | |
| Chihara et al. | AV Schally*, DH Coy*, A. Arimura*, TW Redding*, AJ Kastin*, C. Meyers*, J. Seprodi*, R. Chang*, W.-Y. Huang | |
| SCHALLY et al. | HORMONES (RI-I), ESPECIALLY LH-RH | |
| Sherwood et al. | Primary Structure and Function of Three Gonadotropin | |
| NEKOLA et al. | RECENT ADVANCES IN THE DEVELOPMENT OF LHRH ANTAGONISTS | |
| SCHALLY et al. | Hypothalamie Peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20050603 |